MicroRNA-203 Functions As a Natural Ras Inhibitor in Hepatocellular Carcinoma

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2023 May 11

PMID 37168327

Authors

Jun Guo

Lei Li

Nan Deng

Yong Xu

Guohua Wang

Hongbo Luo

Chuanrui Xu

Xiaolei Li

Affiliations

Soon will be listed here.

Abstract

microRNA-203 (miR203) plays an important role in the formation and development of multiple types of cancers. However, its role in hepatic carcinogenesis has not been well studied. Mitogen-activated protein kinase signaling is known to be activated in hepatocellular carcinoma (HCC), but there is a lack of effective drugs targeting this pathway for HCC treatment. In this study, we investigated the role of miR203 in HCC and the underlying mechanism. We found that miR203 was significantly downregulated in HCC cell lines and patient tissues compared with a hepatocyte cell line (L02) or normal liver tissues. Restoration of miR203 inhibited HCC cell growth and induced cell cycle arrest and apoptosis. In primary and xenograft HCC mouse models, miR203 also significantly blocked HCC growth. Bioinformatic analysis indicated that miR203 directly binds to the 3'UTR of NRas mRNA, resulting in decreased expression of NRas and inactivation of mitogen-activated protein kinase (MAPK) signaling. Activation of MAPK signaling by ectopic NRas expression rescued the cell proliferation blocked by miR203. Together, our findings illustrate the fundamental role of miR203 as a natural inhibitor of RAS/MAPK signaling in hepatic carcinogenesis and . In light of the critical and universal activation of the MAPK pathway in HCC, miR203 has the potential to serve as a nucleotide drug for the treatment of HCC with activated MAPK signaling.

References

Saini S, Majid S, Yamamura S, Tabatabai L, Suh S, Shahryari V . Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res. 2010; 17(16):5287-98. DOI: 10.1158/1078-0432.CCR-10-2619. View

Calvisi D, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M . Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res. 2008; 68(11):4192-200. DOI: 10.1158/0008-5472.CAN-07-6157. View

Hu J, Che L, Li L, Pilo M, Cigliano A, Ribback S . Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep. 2016; 6:20484. PMC: 4746674. DOI: 10.1038/srep20484. View

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Shao Y, Zhang D, Li X, Yang J, Chen L, Ning Z . MicroRNA-203 Increases Cell Radiosensitivity via Directly Targeting Bmi-1 in Hepatocellular Carcinoma. Mol Pharm. 2018; 15(8):3205-3215. DOI: 10.1021/acs.molpharmaceut.8b00302. View

Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S . AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box.... Hepatology. 2011; 55(3):833-45. PMC: 3269553. DOI: 10.1002/hep.24736. View

Huynh H, Nguyen T, Chow K, Tan P, Soo K, Tran E . Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003; 3:19. PMC: 317301. DOI: 10.1186/1471-230X-3-19. View

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

10.

Liu Y, Ren F, Rong M, Luo Y, Dang Y, Chen G . Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int. 2015; 15:62. PMC: 4479344. DOI: 10.1186/s12935-015-0214-0. View

11.

Tanaka N, Lin J, Li C, Ryan M, Zhang J, Kiedrowski L . Clinical Acquired Resistance to KRAS Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021; 11(8):1913-1922. PMC: 8338755. DOI: 10.1158/2159-8290.CD-21-0365. View

12.

Chen H, Kong M, Chen Y, Jiang Y, Wen M, Zhang X . Prognostic significance of miR-203 and ZEB1 expression in early-stage hepatocellular carcinoma. J Cancer. 2021; 12(16):4810-4818. PMC: 8247376. DOI: 10.7150/jca.57819. View

13.

Chen H, Han Z, Fan J, Xia J, Wu J, Qiu G . miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2011; 29(3):1859-65. DOI: 10.1007/s12032-011-0031-9. View

14.

Zhang A, Lakshmanan J, Motameni A, Harbrecht B . MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling. Mol Cell Biochem. 2017; 441(1-2):89-98. DOI: 10.1007/s11010-017-3176-9. View

15.

Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M . Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 2004; 24(5):432-6. DOI: 10.1111/j.1478-3231.2004.0940.x. View

16.

Zheng X, Chen X, Xu L, Zhang M, Feng L, Yi P . miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver. Cancer Sci. 2017; 108(3):338-346. PMC: 5378262. DOI: 10.1111/cas.13167. View

17.

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

18.

Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer C . Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014; 60(2):554-64. PMC: 4809671. DOI: 10.1002/hep.27153. View

19.

Delire B, Starkel P . The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015; 45(6):609-23. DOI: 10.1111/eci.12441. View

20.

Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z . miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct. 2012; 31(1):82-5. DOI: 10.1002/cbf.2863. View